NCT03155932View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 29, 2017

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Primary Biliary Cholangitis
Interventions
DRUG

APD334

APD334 active treatment for 24 weeks.

Trial Locations (9)

1023

Auckland City Hospital, Grafton

2050

Royal Prince Alfred Hospital, Camperdown

3004

Alfred Health, Melbourne

4575

Sunshine Coast University Hospital, Birtinya

8011

Christchurch Clinical Studies Trust, Christchurch

77030

Baylor College of Medicine, Houston

78215

Texas Liver Institute, San Antonio

95817

Gastroenterology and Hepatology, UC Davis Medical Center, Sacramento

98104

Swedish Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Arena Pharmaceuticals

INDUSTRY

NCT03155932 - Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis | Biotech Hunter | Biotech Hunter